Developing a medical device requires expertise from several disciplines, and the decisions made in one area often have significant implications for another. A material selected during mechanical design may affect biocompatibility testing. A software feature may introduce new regulatory requirements. A manufacturing decision can influence validation activities, while changes to the intended purpose can affect the entire development and clinical evidence strategy.

Despite these connections, engineering and regulatory work are sometimes approached as separate activities. Product development progresses according to technical requirements, while quality and regulatory specialists become more heavily involved when testing, documentation or regulatory submissions need to be prepared.

Bringing these areas together earlier can make development more efficient and help manufacturers avoid decisions that lead to unnecessary work later.

This is also the idea behind the collaboration between MDS Life Sciences and Creo Center, who will be exhibiting together at MEDICA 2026. By combining engineering and product development capabilities with quality, regulatory and clinical expertise, we aim to offer medical device manufacturers a more comprehensive approach to developing products and bringing them to market.

Product Development and Regulatory Strategy Should Start Together

The early stages of medical device development involve important decisions about the product’s intended purpose, technical requirements, functionality, materials and manufacturing approach. These decisions determine not only what the device will look like and how it will work, but also what evidence will eventually be needed to demonstrate its safety and performance.

For example, the intended purpose and target users of a device can influence its mechanical design, user interface, software functionality and operating environment. These considerations also affect risk management, usability engineering, verification and validation requirements.

If the engineering and regulatory perspectives are considered together, the development team can evaluate technical alternatives with a better understanding of their regulatory implications.

This does not mean that every design decision needs a separate regulatory assessment. Rather, the objective is to identify the decisions that may significantly affect the development strategy, testing requirements or route to market before they become difficult or expensive to change.

Engineering Decisions Can Have Wider Regulatory Consequences

Material selection is a good example of how technical and regulatory considerations overlap.

A material may have suitable mechanical properties, meet durability requirements and be easy to manufacture. However, depending on the intended application, the manufacturer may also need to consider biological safety, chemical characterization, cleaning or sterilization compatibility and the availability of supporting material documentation.

These questions are easier to address while materials and manufacturing methods are still being evaluated. If they are only raised after the product design has been finalized, the available options may be considerably more limited.

Similar considerations apply to electronics, embedded systems and software.

A new function may be technically straightforward to implement but introduce additional requirements for software verification, usability, cybersecurity or clinical evidence. Design changes may also affect existing risk assessments and the justification for previously completed testing.

With engineering and QA/RA expertise involved in the same discussions, these implications can be considered alongside functionality, manufacturability, development cost and project timelines.

Planning Testing and Validation Around the Actual Device

Testing and validation are among the areas where an integrated approach can make a practical difference.

Medical device manufacturers need to demonstrate that their products meet the applicable safety and performance requirements. However, the specific evidence needed depends on the device, its intended purpose, technical characteristics and regulatory pathway.

An engineering team may be focused on demonstrating that a particular design works as intended. From a regulatory perspective, it is equally important to establish whether the test methods, acceptance criteria, sample configurations and resulting evidence will adequately support the relevant requirements.

For example, mechanical performance testing may need to consider worst-case configurations or conditions identified through risk management. Biological evaluation may require information about the finished device and its manufacturing processes, not only the raw materials. Software verification needs to be traceable to defined requirements and the associated risks.

Planning these activities together helps ensure that engineering work generates evidence that can also be used in the regulatory documentation.

This is particularly valuable when external testing laboratories are involved. Selecting an appropriate laboratory, defining the test scope and agreeing on the samples and methods in advance can help avoid unnecessary testing or situations where completed work does not adequately address the regulatory question.

From Prototypes to Manufacturing

Moving from a working prototype to a product that can be manufactured consistently introduces another set of challenges.

Designs may need to be adapted for production, components and materials must be sourced, suppliers selected, and manufacturing and inspection methods established. Depending on the device and processes involved, additional validation activities may also be required.

These activities are closely connected to quality management.

Supplier selection, purchasing controls, design transfer, process validation and change management all need to be considered as the product moves closer to manufacturing.

Engineering expertise is essential for creating designs that can be manufactured reliably and efficiently. Quality and regulatory expertise helps ensure that the manufacturing approach, supplier arrangements and resulting documentation can support the manufacturer’s regulatory obligations.

Addressing both perspectives during development can reduce the likelihood of discovering significant manufacturing or validation gaps shortly before regulatory submission.

It can also help manufacturers identify suitable external partners for manufacturing, testing, sterilization and other specialist activities, taking both technical capabilities and regulatory expectations into account.

The Same Approach Benefits Established Manufacturers

The value of combining engineering and regulatory expertise is not limited to developing new medical devices.

Established manufacturers regularly introduce product improvements, update software, replace components, change suppliers and adapt designs to improve usability or manufacturing efficiency.

These changes can appear relatively straightforward from an engineering perspective while still requiring careful consideration of their impact on risk management, verification and validation, clinical evidence or regulatory documentation.

For example, replacing a component with a technically equivalent alternative may still require an assessment of material characteristics, existing evidence or supplier-related requirements. Similarly, introducing new software functionality may affect the device’s intended purpose, claims or applicable regulatory requirements.

A coordinated approach allows manufacturers to assess these considerations while the change is being planned, rather than addressing the regulatory implications only after implementation.

Bringing Together the Expertise Needed Throughout Development

The collaboration between Creo Center and MDS Life Sciences is built around these connections between engineering, quality management and regulatory affairs.

Creo Center brings extensive product development capabilities, including industrial and mechanical design, embedded systems, software development, engineering analysis, prototyping and development towards production.

MDS Life Sciences contributes expertise in medical device quality management, regulatory strategy, risk management, technical documentation, clinical and biological evaluation, testing strategies, and EU and US market-entry requirements.

Together, these capabilities can support manufacturers across multiple stages of the development process, from defining product requirements and evaluating technical solutions to planning verification, validation and preparing the evidence needed for market entry.

An important part of this approach is flexibility. Not every manufacturer needs an entirely outsourced development project, and many already have experienced engineering, quality and regulatory teams.

The objective is to provide the additional expertise required for each project, whether that means supporting an internal team with a specific technical or regulatory challenge or coordinating a broader range of development activities.

It also provides an opportunity to address questions that cross traditional areas of responsibility. Engineers can discuss design alternatives directly with regulatory specialists, while quality and clinical considerations can be incorporated into development planning before significant resources have been committed.

For manufacturers, this offers a more coordinated way to access specialist expertise without having to independently identify and manage every technical and regulatory resource.

A More Connected Route From Development to Market

Successful medical device development depends on more than having the right technical solution or completing the necessary regulatory documentation. Both need to support the same product requirements and development objectives.

When engineering, quality management and regulatory strategy are considered together, manufacturers are better positioned to make informed decisions about design, testing, suppliers, manufacturing and market entry.

The benefit is not simply having access to more services. It is being able to involve the right expertise at the appropriate stage of development, reducing unnecessary work and helping the project progress in a more structured and cost-effective way.

MDS Life Sciences and Creo Center will be exhibiting together at MEDICA 2026, from 16–19 November in Düsseldorf, at Hall 17, Booth C04.

We look forward to discussing how our combined expertise can support medical device manufacturers, whether you are developing a new product, improving an existing device or preparing for market entry.

If you’re attending MEDICA, come meet our teams and tell us about your project. You can also get in touch beforehand through here to arrange a meeting. 

MEDICA 2026 | Hall 17, Booth C04 | 16–19 November

Related blogs

Meet MDS Life Sciences and Creo Center at MEDICA 2026

MDS Life Sciences will be exhibiting at MEDICA 2026 together with Creo Center! Join us in Düsseldorf on 16–19 November at Hall 17, Booth C04. This year, we are bringing together our complementary expertise in medical device quality, regulatory affairs and product...

Read More

Biological Evaluation Is More Than Biocompatibility Testing

When biological safety comes up in a medical device project, the first question is often: Which biocompatibility tests do we need? That is understandable, but it is usually not the best place to start. Biological evaluation is not simply a list of laboratory tests. It...

Read More